Free shipping on all orders over $ 500

CEP-33779

Cat. No. M2064
CEP-33779 Structure
Synonym:

CEP33779

Size Price Availability Quantity
5mg USD 120  USD120 In stock
10mg USD 175  USD175 In stock
25mg USD 300  USD300 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CEP-33779 is a highly selective, orally active, small-molecule inhibitor of JAK2. CEP-33779 (< 3 μM) inhibits phosphorylation of downstream target signal transducer and activator of transcription 5 (pSTAT5) of JAK2 in a concentration dependent manner in HEL92 cells. CEP-33779 induced regression of established colorectal tumors, reduced angiogenesis, and reduced proliferation of tumor cells. CEP-33779 results in reduced bone degradation, reduced tissue destruction, and reduced osteoarthritis in dose-dependent manner in CAIA or CIA mice. CEP-33779 suppressed growth of colorectal tumors by inhibiting the IL-6/JAK2/STAT3 signaling. Treatment with CEP-33779 extended survival and reduced splenomegaly/lymphomegaly. Several serum cytokines were significantly decreased upon treatment including IL-12, IL-17A, IFN-α, IL-1β, and TNF-α.

Chemical Information
Molecular Weight 462.57
Formula C24H26N6O2S
CAS Number 1257704-57-6
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Seavey MM, et al. Mol Cancer Ther. Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer.

[2] Lu LD, et al. J Immunol. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.

[3] Stump KL, et al. Arthritis Res Ther. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Related JAK Products
A-005

A-005 is a potentially first-in-class, brain-penetrating TYK2 allosteric inhibitor for studies related to neuroinflammatory and neurodegenerative diseases.

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

JAK2/FLT3-IN-1 TFA

JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively.

ZT55

ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM.

ZM39923

ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: CEP-33779, CEP33779 supplier, JAK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.